Skip to main content

Vegzelma FDA Approval History

Last updated by Judith Stewart, BPharm on Sep 29, 2022.

FDA Approved: Yes (First approved September 27, 2022)
Brand name: Vegzelma
Generic name: bevacizumab-adcd
Dosage form: Injection
Company: Celltrion USA
Treatment for: Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer

Vegzelma (bevacizumab-adcd) is a vascular endothelial growth factor (VEGF) inhibitor biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer including colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Development timeline for Vegzelma

Sep 27, 2022Approval FDA Approves Vegzelma (bevacizumab-adcd), a Biosimilar to Avastin

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.